ASSET ACQUISITION |
9 Months Ended | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2026 | ||||||||||||||||||||||||||||
| Asset Acquisition [Abstract] | ||||||||||||||||||||||||||||
| ASSET ACQUISITION |
Oratech Acquisition
On March 25, 2026, the Company completed the acquisition of Oratech in accordance with the terms of the Share Purchase Agreement (“SPA”) entered into by the parties on January 12, 2026.
As consideration for the transaction, the Company issued an aggregate of 1,250,363 ordinary shares and pre-funded warrants to purchase 1,006,113 ordinary shares. In addition, the Company issued 1,296,296 freestanding warrants to purchase ordinary shares at an exercise price of $5.4 per share and agreed to pay Oramed Pharmaceuticals Inc. (“Oramed”) certain quarterly revenue sharing payments based on future sales.
The Company concluded that the Oratech acquisition should be accounted for as an asset acquisition. As such, the consideration paid in the asset acquisition was allocated to the purchased assets. The asset acquisition total consideration was $12.4 million and was comprised of the fair values of the ordinary shares, pre-funded warrants and warrants. The revenue sharing arrangement was excluded from the initial measurement of consideration based on the Company’s assessment of the applicable accounting guidance, including its determination that the arrangement did not meet the definition of a derivative under ASC 815.
The acquired assets primarily consist of patented technology and cash in the amount of $6.5 million. In connection with the agreement, the Company also entered into a clinical trial management agreement with Oramed in which Oramed will provide clinical trial management services for the Company in connection with the acquired intellectual property. The Company concluded that the costs of the clinical trial services under the agreement are below market value, and as such, the Company recognized approximately $1.0 million as a prepaid asset for future services. The total consideration allocated to the intellectual property was $5.9 million.
The total consideration transferred was allocated to the acquired assets as follows (in thousands):
As the acquired IPR&D asset was determined to have no alternative future use, the allocated value was immediately recognized as research and development expense.
As of the acquisition date, the pre-funded warrants and the freestanding warrants that were allocated to the asset acquisition were classified as liabilities, measured at fair value through earnings, as these instruments did not meet the conditions to be classified as equity under ASC 815-40.
As of June 30, 2026, the pre-funded warrants and the freestanding warrants were reclassified to equity since the warrants met the conditions to be classified as equity under ASC 815-40.
Skelable Acquisition
On May 18, 2026, the Company completed the acquisition of certain technology and related intellectual property assets from Skelable Ltd. pursuant to the terms of the Asset Purchase Agreement.
As consideration for the transaction, the Company paid cash consideration of $20 thousand, issued 34,328 ordinary shares and agreed to issue additional ordinary shares of up to $250 thousand as contingent consideration upon the achievement of specified milestones. The contingent consideration was measured at fair value as of the acquisition date and included in the total consideration transferred.
The Company concluded that the transaction should be accounted for as an asset acquisition. Accordingly, the entire consideration of $442 thousand was allocated to a single finite-lived intangible asset, consisting of the acquired technology. The intangible asset is being amortized on a straight-line basis over its estimated useful life of 5 years. During the three and nine months ended September 30, 2026, the Company recognized amortization expense of approximately $23 thousand and $33 thousand, respectively, related to this intangible asset. |
|||||||||||||||||||||||||||